CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- 4 Shares withheld for taxes Chief Financial Officer gave up 11,962 shares (to pay taxes)
- 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $6.35 ($190,434)
- 4 Planned sale Chief Executive Officer sold 50,000 shares at an average $6.86 ($343,000)
- 4 Planned sale Director sold 11,447 shares at $6.82 ($78,083)
- 4 Grant or award Chief R&D Commercial Officer acquired 496,972 shares (grant or award)
- 4 Planned sale President and COO sold 6,000 shares at $8.13 ($48,809)
- 4 Planned sale Director sold 11,447 shares at $8.48 ($97,041)
- 4 Planned sale Chief Executive Officer sold 100,000 shares at an average $7.48 ($747,500)
- 4/A Conversion Chief Executive Officer acquired 100,000 shares (conversion)
- 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $7.28 ($218,354)
- 4 Planned sale Director sold 11,447 shares at $7.32 ($83,735)
- 4 Grant or award Director acquired 1,592 shares (grant or award)
- 4 Grant or award Director acquired 1,843 shares (grant or award)
- 4 Grant or award Director acquired 1,843 shares (grant or award)
- 4 Grant or award Director acquired 1,441 shares (grant or award)
- 4 Planned sale President and COO sold 6,000 shares at $7.22 ($43,290)
- 4 Planned sale Director sold 11,447 shares at $9.51 ($108,806)
- 4 Planned sale Chief Financial Officer sold 30,000 shares at an average $9.30 ($278,880)
- 4 Planned sale Director sold 11,447 shares at $8.45 ($96,763)
- 4 Planned sale Chief Executive Officer sold 100,000 shares at an average $8.71 ($871,000)
Page 9 of 26 · 512 filings